Heidi Ko, Medical Director, Medical Affairs at Labcorp Drug Development, shared on LinkedIn:
“As a clinician at heart, I’m truly excited to see Inside Precision Medicine highlight our work in advancing personalized cancer care.
Labcorp’s expanded DPYD genotyping helps identify patients at increased risk for significant toxicity from 5-FU and capecitabine before treatment begins, enabling more informed decisions and, ultimately, safer delivery of therapy for our patients!
Thank you Annette Taylor for your leadership in this field and for helping advance such a critically important test for patients.”
Other articles featuring Heidi Ko on OncoDaily.